role has been mostly investigated in post-treatment setting. We assessed the diagnostic accuracy of 68Gallium-PSMA PET to predict LN metastases in primary N-staging in high andvery high-risk non-metastatic prostate cancer in comparison with morphologic imaging.
INTRODUCTION AND OBJECTIVES:
A 2008 mapping study showed that primary lymphatic landing sites of the prostate are also found medially to the internal iliac vessels, in the fossa of Marcille and along the common iliac vessels up to the ureter crossing. We then expanded our PLND template accordingly (Graphic). We assessed the effects of the template revision on pathologic and complication outcomes.
METHODS: 753 pts underwent RP and extended PLND from 2000 to 2008 (485 pts [64%] ; historical cohort) and from 2010 to 2015 (268 [36%] ; contemporary cohort) at a referral center. Descriptive statistics and a logistic regression model were used. Subanalysis of patients with ¼2 metastases was performed because these patients are the ones who may most benefit from removal of LN metastases.
RESULTS: Median number of LN removed in the historical cohort was 25 and in the contemporary cohort 34 (27-43; p <0.0001). Among 80 N+ pts (16%) in the historical cohort, the sole location of metastasis was external iliac/obturator region in 23/80 (29%) and internal iliac in 18/80 (23%), while 39/80 (49%) had metastases in both locations. Among 72 N+ pts (27%) in the contemporary cohort, the sole location of metastasis was external iliac/obturator region in 17 (24%) patients, internal iliac region in 24 (33%), and common iliac region in 1 (1%), while 30 (42%) had metastases in more than one location. While 5 patients had LN metastases in the fossa of Marcille, the latter was never the exclusive location. However, among pts with ¼2 metastases in the contemporary cohort, 3 pts had one or both metastases in the common iliac regions or in the fossa of Marcille only. The adjusted risk to harbor nodal metastases was higher in the contemporary cohort, albeit not significantly (OR 1.19, p¼0.4) . Complications such as lymphoceles, thrombosis and neuropraxia were no more frequent with a more extended template.
CONCLUSIONS: A more extended PLND template detects LN metastases in the common iliac regions and in the fossa of Marcille and is associated with an overall non-significant higher risk of harboring LN metastases.
Source of Funding: none

MP20-17 THE IMPACT OF NODE POSITIVE DISEASE FOLLOWING RADICAL PROSTATECTOMY ON SURVIVAL: A CONTEMPORARY POPULATION-BASED COHORT
Ron Golan*, Adrien Bernstein, Wei-Chun Hsu, Brian Dinerman, Michael Cosiano, Jonathan E. Shoag, Art Sedrakyan, Jim C. Hu, New York, NY INTRODUCTION AND OBJECTIVES: With the professional guidelines pulling back on the utility and frequency of prostate cancer screening, there is concern there will be a stage shift with an increase in lymph node metastases. Against this backdrop, the objective of our contemporary, population-based study was to examine outcomes associated with pelvic lymph node metastases.
METHODS: We identified 161,079 radical prostatectomies during 2004-2014 using the Surveillance, Epidemiology, and End Results (SEER). Propensity score matching was used to adjust for confounding. Time to event analysis were used to compare all-cause mortality as well prostate cancer-specific mortality for those with (pN+) and without (pN-) pelvic lymph node metastases.
RESULTS: From the total, we identified 3,697 radical prostatectomy pN+ (2.3%). Older age, higher grade and higher tumor stage were associated with pN+ (p<0.01, respectively). After propensity matching, pN+ disease was associated with higher all-cause mortality (28.5 vs 10.8 deaths per 1,000 person years, p<0.001) as well as higher prostate cancer-specific mortality (17.5 vs 3.5 deaths per 1,000 person years, p<0.01), with a median follow-up of 3.6 years ( Figure 1) . A higher number of positive lymph nodes was strongly associated with worse overall survival and prostate cancer-specific survival (Figure 2) .
CONCLUSIONS: In light of our SEER studies demonstrating a recent increase in prostate cancer metastatic disease, it is worth noting that men with pN+ have significantly poorer outcomes. The effect on mortality was further increased by the number of positive lymph nodes. The outcomes from our study may guide men concerning adjuvant therapies and clinical trials. 
INTRODUCTION AND OBJECTIVES:
Among men with localized high-risk prostate cancer (PCa), patients who met very-high-risk (VHR) criteria were shown to experience inferior outcomes after radical prostatectomy (RP) in a previous single institution study. Using a multiinstitutional dataset, here we compared pathologic and oncologic outcomes between men with high-risk and VHR PCa who underwent RP between 2005-2015. METHODS: High-risk PCa was defined as biopsy Gleason pattern 8-10, PSA >20 ng/ml, or clinical stage T3-4. VHR PCa was defined according to pre-treatment criteria: primary Gleason pattern 5 on biopsy; or ¼ 5 cores containing Gleason sum 8-10; or multiple high-risk features. Pathologic outcomes by risk classification were compared using Chi-squared testing, and oncologic outcomes (biochemical recurrence -BCR, metastasis -METS, cancer specific mortality -CSM, and overall mortality -OM) were assessed using Cox proportional hazards models. Multivariable models included age, race, institution, and neoadjuvant androgen deprivation therapy as covariates.
RESULTS: Among 1776 high-risk patients, 547 (30.8%) met VHR criteria. As compared to the high-risk cohort, VHR men had inferior pathologic outcomes. Positive margins: 38% vs 25%. Stage pT3b-4: 46% vs 17%. Stage pN1: 41% vs 15%. (P<0.001 for all comparisons) . Over a median follow-up of 3 years, VHR PCa patients also had higher adjusted hazard ratios for BCR (2.32), METS (3.87), CSM (4.14), and OM (2.66). (P<0.001 for all comparisons).
CONCLUSIONS: In a multi-institutional experience of 1776 men who underwent treatment for high-risk PCa over a 10-year period, VHR cancer was strongly associated with adverse pathologic and oncologic outcomes as compared to high-risk disease. These findings serve to validate the prognostic significance of VHR PCa as a distinct entity from high-risk PCa, suggesting that VHR criteria should be considered during patient counseling and as a potential risk stratification tool in clinical trials. INTRODUCTION AND OBJECTIVES: Prostate-specific antigen doubling time (PSADT) is a useful marker for assessing disease aggressiveness at multiple stages of prostate cancer. However, in men with non-metastatic castration resistant prostate cancer (M0 CRPC), there are no commonly used PSADT cut-points for risk stratification. We examined whether PSADT correlates with metastases, all-cause mortality (ACM), and prostate cancer-specific mortality (PCSM) and identified PSADT cut-points that can be used clinically for risk stratification in men with M0 CRPC.
METHODS: We collected data on 441 men with M0 CRPC in 2000-2015 at five Veterans Affairs hospitals. Cox models were used to test the association between log-transformed PSADT and development of metastasis, ACM, and PCSM. To identify cut-points, we categorized PSADT into groups of every 3 months (<3, 3-5.9, 6-8.9, 9-11.9, 12-14.9, 15-17.9, 18-20.9, 21-23.9, 24-119.9, 120) and then combined groups with similar hazard ratios. We tested the association between PSADT cut-points and each outcome using Cox models and compared survival using Kaplan-Meier estimates.
RESULTS: Median age was 77 months (IQR: 70-83) and 160 (36%) men were black. Median PSADT was 13.3 months (IQR: 6.4-94.3) and median follow-up was 28.3 months (IQR: 14.7-49.1). As a continuous variable, PSADT was associated with metastases, ACM, and PCSM (HR 1.40-1.68, all p<0.001). We identified the PSADT cutpoints <3, 3-8.9, 9-14.9, 15 months. As a categorical variable, PSADT was associated with metastases, ACM, and PCSM (all p<0.001). Men
